title: [Treatment of vestibular vertigo and Ménière syndrome in outpatient clinics].
abstract: An aim of this study was to assess clinical efficacy and tolerability of tagista in the symptomatic treatment of vestibular vertigo and Ménière syndrome. Thirty-two patients, 16 women and 16 men, aged from 25 to 67 years, were examined. Vertigo was caused by chronic brain ischemia in 17 cases and by the disturbance of blood circulation in the vertebral-basilar system in 14 patients with osteochondrosis of cervical spine. One patient was diagnosed with Ménière syndrome. Tagista was used in dose 24 mg twice a day during 4 weeks in the combination with standard treatment, exercise therapy and stability training. The results revealed a statistically significant effect of the drug on main symptoms (frequency, duration and intensity of vertigo attacks etc) and its good tolerability that allowed to recommend the drug in neurological practice.
authors: E V
authors: EV
authors: Kostenko
authors: L V
authors: LV
authors: Petrova
authors: E A
authors: EA
authors: Torgovanova
authors: P A
authors: PA
authors: Ganzhula
authors: L N
authors: LN
authors: Lisenker
authors: O V
authors: OV
authors: Otcheskaia
authors: A A
authors: AA
authors: Khozova
authors: A V
authors: AV
authors: Lebedeva
authors: A N
authors: AN
authors: Boĭko
mesh_terms: D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities; D001621:Betahistine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015444:Exercise; D005260:Female; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome; D014717:Vertigo / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D001621:Betahistine